RBO & Co. LLC Purchases New Position in Pfizer Inc. $PFE

RBO & Co. LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) in the first quarter, HoldingsChannel reports. The institutional investor purchased 29,600 shares of the biopharmaceutical company’s stock, valued at approximately $750,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Brighton Jones LLC grew its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC grew its position in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the period. Integrated Wealth Concepts LLC grew its position in Pfizer by 0.7% during the fourth quarter. Integrated Wealth Concepts LLC now owns 492,149 shares of the biopharmaceutical company’s stock worth $13,057,000 after buying an additional 3,392 shares during the period. Voya Financial Advisors Inc. grew its position in Pfizer by 4.7% during the fourth quarter. Voya Financial Advisors Inc. now owns 41,288 shares of the biopharmaceutical company’s stock worth $1,091,000 after buying an additional 1,841 shares during the period. Finally, Cheviot Value Management LLC grew its position in Pfizer by 5.9% during the fourth quarter. Cheviot Value Management LLC now owns 440,622 shares of the biopharmaceutical company’s stock worth $11,690,000 after buying an additional 24,562 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE opened at $25.8250 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market capitalization of $146.83 billion, a price-to-earnings ratio of 13.74, a PEG ratio of 0.92 and a beta of 0.52. The company’s 50 day simple moving average is $24.70 and its 200 day simple moving average is $24.42. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Analysts Set New Price Targets

Several research firms have recently commented on PFE. Morgan Stanley increased their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Leerink Partners lowered their price target on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a research report on Wednesday, April 30th. The Goldman Sachs Group increased their price target on shares of Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Wolfe Research increased their price target on shares of Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research report on Wednesday, April 30th. Finally, Bank of America increased their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.